Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Roger A. Babb who wrote (2323)	2/5/1998 9:41:00 AM
From: Amots	Read Replies (2) \| Respond to of 18691

Roger. One more play: <<Interferon Sciences Completes $7.6 Million Private Offering NEW BRUNSWICK, N.J., Feb. 5 /PRNewswire/ -- Interferon Sciences, Inc. (Nasdaq: IFSC) announced today that it raised $7,500,000 through the sale of 7,500 shares of the Company's Series A Convertible Preferred Stock to an institutional investor. The Preferred Stock will accrue dividends at the rate of 6% per annum, payable in cash or in Common Stock. The Preferred Stock (including unpaid dividends) is convertible into the Company's Common Stock at a price equal to the lesser of $12.50 or a discount of 5 to 15% from the weighted average trading price of the Common Stock over the 1 0 trading days prior to conversion, subject to certain adjustments. The Preferred Stock is subject to redemption at the option of the Company or the holder under certain circumstances. All of the shares of Preferred Stock must be redeemed on the third anniversary of closing. "The private placement funds augment our working capital as we await the results of our two Phase 3 clinical trials of ALFERON N Injection(R), the Company's highly purified, natural-source, multispecies alpha interferon, for the treatment of HIV-infected and hepatitis C patients," commented Lawrence M. Gordon, Chief Executive Officer of the Company. "This financing helps solidify our financial position for the upcoming year." Interferon Sciences, Inc. is a biopharmaceutical company engaged in the manufacture and sale of pharmaceutical products based on its highly purified, natural-source, multispecies alpha interferon. The Company's ALFERON N Injection (Interferon Alfa-n3) product has been approved by the United States Food and Drug Administration for the treatment of certain types of genital warts, and is being studied for potential use in other indications. The Company also has other natural-source alpha interferon formulations in various stages of development for the potential treatment of viral and immune system diseases. Interferon Sciences' press releases are posted on the Company's website located at interferonsciences.com. They are also available by facsimile 24 hours per day at no charge by calling PR Newswire's Company News On-Call at 800-758-5804, ext. 445138. The forward-looking statements contained herein reflect ISI management's current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward- looking statements, all of which are difficult to predict and many of which are beyond the control of ISI, including, but not limited to, those risks and uncertainties detailed in ISI's periodic reports and registration statements filed with the Securities and Exchange Commission. Interferon Sciences, Inc ... Advancing immunotherapy naturally SOURCE Interferon Sciences, Inc. CO: Interferon Sciences, Inc. ST: New Jersey IN: MTC SU: OFR >> Amots

To: Roger A. Babb who wrote (2323)	2/5/1998 1:15:00 PM
From: Ploni	Read Replies (1) \| Respond to of 18691

Subject: IIML Here's one to keep an eye on: biz.yahoo.com iMall Elects Six New Directors, Adds Three Senior Executives and Will Apply for Nasdaq This Month In Anticipation of a Nasdaq Listing, Internet Company Says it Has Notified NASD of its Intention to Reverse Split Common Stock One-For-Eight

To: Roger A. Babb who wrote (2323)	2/5/1998 1:38:00 PM
From: Dante Sinferno	Read Replies (1) \| Respond to of 18691

LOCK..... Quantum Group, Ltd. Begins Coverage of Saf-T-Lok With a Sell Recommendation NEW YORK, Feb. 5 /PRNewswire/ -- The following was issued today by Quantum Group, Ltd.: Saf-T-Lok (Nasdaq: LOCK) has enjoyed a recent appreciation of over 300 percent in the price of their shares. This Florida-based company is in the business of marketing a combination trigger lock for guns. Quantum believes the recent rise in the stock is due to the incentives that were given to a PR firm and a brokerage firm. If the shares of Saf-T-Lok trade above 3 dollars a share state street securities, marketing direct concepts and a business consulting firm receive over 2 million dollars. Quantum believes this incentive has caused aggressive marketing of the stock that has pushed the shares of Saf-T-Lok to unrealistically high levels. Sales The latest reporting quarter Saf-T-Lok reported sales of 5 thousand dollars and a $300,000 loss. Saf-T-Lok has a marketing plan similar to last year which leads Quantum to believe the sales of Saf-T-Lok will not be significant in the short term. Saf-T-Lok issued a recent press release saying that they received an order totaling $550,000 from a newly formed company called United Safety Action Inc. based in Muncy, N.Y. From Quantum's understanding this is a newly formed company without a sales force whose principal has limited experience in the firearms industry. These facts cause Quantum to believe this sale may be an indication of interest and may not follow through. Quantum believes Saf-T-Lok will remain unprofitable for the foreseeable future as they have not demonstrated any ability to generate sales of these patented locks. Market Capitalization Saf-T-Lok currently has over 15 million fully diluted shares outstanding. The current market capitalization is over 75 million dollars. Saf-T-Lok is in an industry that Quantum believes would not command a high price earnings ratio even if the company ever was to be profitable. Gun manufacturers estimate this industry grows at a rate under 5% per year. To justify current valuations, Quantum feels Saf-T-Lok would have to earn in excess of 8 million after tax dollars per year. Saf-T-Lok would have to capture a significant part of the market to accomplish this. Major gun manufacturers have come out with announcements that they are equipping new guns with products other than Saf-T-Loks. Quantum believes this current market capitalization will not be maintained. Insider Stock Sales Over the last year officers and directors have sold their shares in Saf-T-Lok at an alarming rate. Franklin Brooks, the inventor of Saf-T-Lok has sold over 280,000 shares. William Schmidt has sold 88,000 shares. John Gardner, the newly appointed president sold 200,000 shares. Eugene Horanoff sold 47,000 shares. Jeffrey Brooks recently sold 50,000 shares. These sales make Quantum question the confidence this management has in Saf-T-Lok. Conclusion Quantum believes the shares of Saf-T-Lok are currently trading at unsustainable levels. Recent speculation and aggressive marketing of the stock of Saf-T-Lok have driven the shares to an unrealistic price. This is a company that has generated nothing but losses and will continue to do so for the near future. Quantum believes the rise of these shares is a function of short term incentives and not because of company fundamentals. Quantum is setting a twelve month target of under 1 dollar a share.